Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2012 Financial Results Conference Call

  Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2012
  Financial Results Conference Call

Business Wire

BEDFORD, Mass. -- February 14, 2013

Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue
its fourth-quarter and year-end 2012 financial results after the close of the
market on Wednesday, February 27, 2013. The company plans to hold a conference
call the next day, Thursday, February 28 at 9:00 a.m. ET to discuss its
financial results, business highlights and outlook. In addition, the company
will answer questions concerning business and financial developments and
trends, and other business and financial matters affecting the company, some
of the responses to which may contain information that has not been previously
disclosed.

To listen to the conference call, dial 800-291-5365 (international callers
dial 617-614-3922) and use the passcode 89264114. In addition, the call will
be available through a live audio webcast in the "Investor Relations" section
of Anika’s website, www.anikatherapeutics.com. An accompanying slide
presentation also can be accessed via the Anika Therapeutics website. The call
will be archived and accessible on the same website shortly after its
conclusion.

The webcast also is being distributed through the Thomson StreetEvents
Network. Individual investors can listen to the call at www.earnings.com,
Thomson's individual investor portal, powered by StreetEvents. Institutional
investors can access the call via Thomson StreetEvents (www.streetevents.com),
a password-protected event management site.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
manufactures and commercializes therapeutic products for tissue protection,
healing, and repair. These products are based on hyaluronic acid (HA), a
naturally occurring, biocompatible polymer found throughout the body. Anika’s
products range from orthopedic/joint health solutions led by Orthovisc^®, a
treatment for osteoarthritis of the knee; to surgical aids in the ophthalmic
and anti-adhesion fields. The company also offers aesthetic dermal fillers for
the correction of facial wrinkles. Anika’s Italian subsidiary, Anika
Therapeutics S.r.l, provides complementary HA products in orthopedic/joint
health and anti-adhesion, as well as therapeutics in new areas such as
advanced wound treatment and ear, nose and throat care. Its regenerative
tissue technology advances Anika’s vision to offer therapeutic products that
go beyond pain relief to protect and restore damaged tissue.

Contact:

Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., 781-457-9000
CEO
or
Kevin W. Quinlan, 781-457-9000
CFO
 
Press spacebar to pause and continue. Press esc to stop.